<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429493</url>
  </required_header>
  <id_info>
    <org_study_id>2011/541</org_study_id>
    <nct_id>NCT01429493</nct_id>
  </id_info>
  <brief_title>Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases</brief_title>
  <official_title>Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In various common cancers, the skeleton is a preferred site of metastasis. These bone
      metastases are the most common cause of cancer-related pain, which significantly impair
      quality of life. It is postulated that the clinical target volume (CTV) of painful bone
      metastases consists of cancer cells and tumor-associated host cells: the tumor-host
      ecosystem. Advances in biological imaging (positron emitting tomography PET) might allow us
      to selectively identify the tumor-host ecosystem within the anatomical boundaries of a bone
      metastasis. These findings suggest the potential of intentionally non-homogenous dose
      escalation (dose painting by numbers) to improve pain control. The hypothesis is that
      fluorodeoxyglucose positron emitting tomography (FDG-PET) can detect the intra-bone
      metastasis regions confined with tumor-associated host-cell compartments responsible for
      metastasis-related pain. The primary objective is to improve pain control with biological
      image-guided stereotactic body radiotherapy compared to conventional radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of pain response 1 month after radiotherapy</measure>
    <time_frame>1 month after radiotherapy</time_frame>
    <description>Pain is measured with the visual analogue scale. Response is scored in accordance to the guidelines of the international consensus on palliative radiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life 1 month after radiotherapy.</measure>
    <time_frame>1 Month after radiotherapy</time_frame>
    <description>Quality of life 1 month after radiotherapy measured with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Bone Metastases Module (QLQ-BM22).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biological image-guided radiotherapy with conventional dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biological image-guided SBRT with dose-escalation.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional Radiotherapy</intervention_name>
    <description>Conventional radiotherapy will be used (8 Gy/ 1 fraction).</description>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Biological image-guided radiotherapy with conventional dose.</intervention_name>
    <description>Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.</description>
    <arm_group_label>Biological image-guided radiotherapy with conventional dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Biological image-guided SBRT with dose-escalation.</intervention_name>
    <description>Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.</description>
    <arm_group_label>Biological image-guided SBRT with dose-escalation.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Painful bone metastasis of solid tumors

          -  Pain score minimum of 2 on a scale of 10

          -  A maximum number of painful bone metastases: 3 or more

          -  Life expectancy &gt; 3 months

          -  Age minimum 18 years old

          -  Signed informed consent

        Exclusion Criteria:

          -  Tumor histology (renal cell and melanoma vs. other solid tumors)

          -  VAS pain score (&lt;5 vs. 6-10).

          -  Bisphosphonate use (yes vs. no)

          -  Opioid analgesics (yes vs. no)

          -  Corticosteroid use (yes vs. no)

          -  Spine vs non-spine localisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried De Neve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piet Ost, MD</last_name>
    <phone>09/3323074</phone>
    <email>piet.ost@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Van Gestel, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Dirk Van Gestel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilfried De Neve, MD, PhD</last_name>
      <phone>+32(0)93323074</phone>
      <phone_ext>+32</phone_ext>
      <email>wilfried.deneve@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Wilfried De Neve, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Vandewiele, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Indira Madani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piet Ost, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno De Potter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

